SAREPTA THERAPEUTICS, INC. — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/fd5896d3-29cc-497c-8441-0f19209c36e6/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.9B | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-084144 |
| FY 2024 | $1.8B | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029973 |
| FY 2023 | $1.1B | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-022036 |
| FY 2022 | $843.8M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005062 |
| FY 2021 | $612.4M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002517 |
| FY 2020 | $455.9M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009835 |
| FY 2019 | $380.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-006769 |
| FY 2018 | $301.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005170 |
| FY 2017 | $154.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-005170 |
| FY 2016 | $5.4M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-005170 |
| FY 2015 | $1.3M | 2015-01-01 – 2015-12-31 | evidence 0001564590-17-002842 |
| FY 2014 | $9.8M | 2014-01-01 – 2014-12-31 | evidence 0001564590-17-002842 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
SAREPTA THERAPEUTICS, INC. — all facts · Net Income · Operating Income